The DOI matches its Crossref record; 350 of the 371 references it cites were found in a registry or an index; 47 of the 103 sources its claims cite were checked for support.
Diabetic Gastroparesis.
Open accessAbstract
This review covers the epidemiology, pathophysiology, clinical features, diagnosis, and management of diabetic gastroparesis, and more broadly diabetic gastroenteropathy, which encompasses all the gastrointestinal manifestations of diabetes mellitus. Up to 50% of patients with type 1 and type 2 DM and suboptimal glycemic control have delayed gastric emptying (GE), which can be documented with scintigraphy, 13C breath tests, or a wireless motility capsule; the remainder have normal or rapid GE. Many patients with delayed GE are asymptomatic; others have dyspepsia (i.e., mild to moderate indigestion, with or without a mild delay in GE) or gastroparesis, which is a syndrome characterized by moderate to severe upper gastrointestinal symptoms and delayed GE that suggest, but are not accompanied by, gastric outlet obstruction. Gastroparesis can markedly impair quality of life, and up to 50% of patients have significant anxiety and/or depression. Often the distinction between dyspepsia and gastroparesis is based on clinical judgement rather than established criteria. Hyperglycemia, autonomic neuropathy, and enteric neuromuscular inflammation and injury are implicated in the pathogenesis of delayed GE. Alternatively, there are limited data to suggest that delayed GE may affect glycemic control. The management of diabetic gastroparesis is guided by the severity of symptoms, the magnitude of delayed GE, and the nutritional status. Initial options include dietary modifications, supplemental oral nutrition, and antiemetic and prokinetic medications. Patients with more severe symptoms may require a venting gastrostomy or jejunostomy and/or gastric electrical stimulation. Promising newer therapeutic approaches include ghrelin receptor agonists and selective 5-hydroxytryptamine receptor agonists.
Overview
CoChat Summary
TL;DR
This review synthesizes the epidemiology, pathophysiology, clinical features, diagnosis, and management of diabetic gastroparesis and the broader diabetic gastroenteropathy. It emphasizes that delayed gastric emptying is common but often asymptomatic, and that management is guided by symptom severity, degree of emptying delay, and nutritional status.
Key findings
- Up to 50% of patients with type 1 and type 2 diabetes mellitus and suboptimal glycemic control have delayed gastric emptying; the remainder have normal or rapid emptying. Many with delayed emptying are asymptomatic, while up to 50% of patients have significant anxiety and/or depression.
- In Olmsted County, the age-adjusted prevalence of definite gastroparesis per 100,000 persons was higher in women (37.8; 95% CI, 23.3–52.4) than men (9.6; 95% CI, 1.8–17.4); 25% of definite, 31% of definite/probable, and 46% of any-definition gastroparesis cases had diabetes.
- Over 10 years, gastroparesis developed in 5% of type 1 diabetes (HR, 33; 95% CI, 4.0–274 vs controls), 1% of type 2 diabetes (HR, 7.5; 95% CI, 0.8–68), and 1% of controls; risk was greater in type 1 than type 2 diabetes (HR, 4.4; 95% CI, 1.1–17). In the T1D Exchange registry, 4.8% had a clinical diagnosis of gastroparesis, higher in women (5.8%) than men (3.5%).
- Pathogenesis implicates hyperglycemia, autonomic neuropathy, and enteric neuromuscular inflammation/injury; full-thickness gastric biopsies show loss of interstitial cells of Cajal, loss of enteric nerves, and immune infiltrate, with ICC number correlated with faster 4-hour gastric emptying. Management includes dietary modification, supplemental oral nutrition, antiemetics/prokinetics, and for severe symptoms venting gastrostomy/jejunostomy and/or gastric electrical stimulation; newer approaches include ghrelin receptor agonists and selective 5-hydroxytryptamine receptor agonists.
Methods
- Narrative review covering epidemiology, pathophysiology, clinical features, diagnosis, and management of diabetic gastroparesis and diabetic gastroenteropathy.
- Evidence is drawn from cited clinical and population-based studies, including Olmsted County/Rochester Epidemiology Project studies, the T1D Exchange clinic registry, the NIDDK consortium, and the Nationwide Inpatient Sample.
- Included studies generally defined delayed gastric emptying by objective assessment with scintigraphy, a wireless motility capsule, or a gastric emptying breath test; scintigraphy is described as the criterion standard.
Limitations
- The paper states that no studies have evaluated the prevalence of delayed gastric emptying among randomly selected community members; population-based studies were based on patients who sought care, and the T1D Exchange diagnostic criteria are unclear. It also notes that Nationwide Inpatient Sample data are not broken down separately for idiopathic and diabetic gastroparesis, and that the extent to which survival is affected by comorbid conditions or gastroparesis severity is unknown.
- The paper notes that distinguishing dyspepsia from gastroparesis is often based on clinical judgement rather than established criteria, and that it is uncertain whether quality-of-life differences exist between idiopathic and diabetic gastroparesis.
- Evident from the provided text: the full article is truncated, so later sections on diagnosis and management are not fully available for summary; as a review, it reports no new primary data.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
37 Valid · 11 Not valid · 40 Not checked · 14 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Autonomic dysfunctions are correlated with GI dysmotility (56) and cardiovascular vagal dysfunction is associated with delayed GE in some (58, 59), but not all, studies (1).”
What the sources say
- Supportedcites [58] Bharucha, 2015, Delayed gastric emptying is associated with early and long-term hyperglycemia in type 1 diabetes mellitus, Gastroenterology source
The citation is attached to “but not all, studies.” In the Results (Relationship between Complications of DM and Gastric Emptying – Univariate Analysis; page unavailable), this study found no statistically significant difference in the prevalence of defined cardiac autonomic neuropathy between delayed- and normal-GE groups, although a separate measure of cardiovagal function was associated with delayed GE. It therefore supports the cited exception, with that measurement distinction. (LLM, conf=0.87)
- Disputedcites [59] Bharucha, 2015, Relationship between glycemic control and gastric emptying in poorly controlled type 2 diabetes, Clin Gastroenterol Hepatol sourceExperimental — accuracy not yet measured
The citation to this paper is attached to the claim that some studies did not find an association. The paper’s Discussion instead says vagal dysfunction was associated with delayed gastric emptying in this study; the Results report the association at P<.05. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Supportedcites [1] Chakraborty, 2019, GI dysfunctions in diabetic gastroenteropathy, their relationships with symptoms, and effects of a GLP-1 antagonist, J Clin Endocrinol Metab source
The citation to this paper is attached to the “but not all studies” qualification. In the Cardiovascular autonomic nervous functions section, the study reports that vagal dysfunction was not associated with slower gastric emptying of solids among patients with diabetes. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The overall age-adjusted prevalence of definite gastroparesis per 100,000 persons was approximately fourfold higher in women (37.8; 95% CI, 23.3, 52.4) than in men (9.6; 95% CI, 1.8, 17.4).”
What the sources say
- Supportedcites [4] Jung, 2009, The incidence, prevalence, and outcomes of patients with gastroparesis in Olmsted County, Minnesota, from 1996 to 2006, Gastroenterology source
The Results section, under “Incidence and prevalence of gastroparesis,” reports age-adjusted prevalence of definite gastroparesis of 37.8 per 100,000 women (95% CI, 23.3–52.4) and 9.6 per 100,000 men (95% CI, 1.8–17.4). It gives a female-to-male ratio of 3.9:1, consistent with “approximately fourfold.” (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Among the patients enrolled in this registry who were >26 years of age and had DM for at least 2 years, 4.8% received a clinical diagnosis of gastroparesis (13).”
What the sources say
- Partly supportedcites [13] Aleppo, 2017, Reported gastroparesis in adults with type 1 diabetes (T1D) from the T1D Exchange clinic registry, J Diabetes Complications sourceExperimental — accuracy not yet measured
The Subjects, materials, and methods passage defines the cohort as participants aged ≥26 years with T1D for at least two years, and the Results report a clinical gastroparesis diagnosis in 4.8% of that cohort. The citing sentence says >26 years, which excludes 26-year-olds included in the reported figure. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Because the study only captured patients who presented for care, it does not include people who did not have a GE study.”
What the sources say
- Partly supportedcites [6] Choung, 2012, Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population, Am J Gastroenterol sourceExperimental — accuracy not yet measured
The Discussion says the study may have missed people who did not visit a physician for gastroparesis symptoms, supporting the care-seeking limitation. But Methods > Ascertainment of Gastroparesis says potential cases were identified through either a diagnostic index or a gastric-emptying test database; it does not make a gastric-emptying study a requirement for inclusion. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The risk of gastroparesis was greater in type 1 DM than in type 2 DM (HR, 4.4; 95% CI, 1.1, 17).”
What the sources say
- Supportedcites [6] Choung, 2012, Risk of gastroparesis in subjects with type 1 and 2 diabetes in the general population, Am J Gastroenterol source
The Results section (‘Gastroparesis in Subjects with Type 1 or 2 DM versus Controls’) directly reports a significantly greater risk of developing gastroparesis in type 1 than type 2 DM, with HR 4.4 and 95% CI 1.1–17. No page number is supplied for the passage. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
52 more claims · 17 with their cited sources checked
Create a free account to see all 102 claims and every source verdict.
- It may state two separate claims as one. 31
- Probably not a substantial claim. 15
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in the gastric fundus, impaired inhibitory neurotransmission is accompanied by reduced tonic contraction because of defective muscle contractility, whereas in the antrum both cholinergic neuromuscular transmission and smooth muscle strength are altered [19, 23, 42, 43].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In diabetes, chronic hyperglycemia, and reduced trophic factors, in particular the reduction of KIT/stem cell factor (SCF), cause the loss or dysfunction of ICCs [52], leading to dysregulated gastric emptying [4, 19, 53].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“while psychological factors (anxiety, depression, and somatization) may modulate symptom severity despite similar objective findings [4, 18–20].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [19]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The interplay between autonomic neuropathy, impaired enteric neurotransmission, and loss or dysfunction of interstitial cells of Cajal produces a motility disorder that disrupts the temporal coordination between meal ingestion, gastric processing, intestinal absorption, and insulin pharmacodynamics.”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [19]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“As a consequence, gastroparesis profoundly affects postprandial glycemic excursions, insulin requirements, and the overall management of diabetes [15, 19, 23, 88, 89].”
From Diabetic gastroparesis: pathophysiology and impact on insulin timing choices (2026) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Abstract
“During 10 years, gastroparesis developed in 5.2% (DM1), 1% (DM2), and 0.2% (controls)”
§ Abstract
“The cumulative incidence of symptoms and delayed GE during 10 years was 5% in type 1 DM [hazard ratio (HR), 33; 95% CI, 4.0, 274, adjusted for age and sex vs controls], 1% in type 2 DM (HR, 7.5; 95% CI, 0.8, 68, adjusted for age and sex vs controls), and 1% in controls.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“Follow-up of 1374 patients (269 with DM1, 409 DM2) and controls matched for age and sex (735) in Olmsted County, MN”
Reported 1374 · recomputed 1413
Citations
Cites
The Prevalence of Comorbid Depression in Adults With Diabetes
Anderson, R. J., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.1069 · Cited by 3,926
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Depression and poor glycemic control: a meta-analytic review of the literature.
Lustman, P. J., Anderson, R. J., Freedland, K. E., de Groot, M., Carney, R. M., & Clouse, R. E. (2000) · Diabetes Care · doi:10.2337/diacare.23.7.934 · Cited by 1,854
Association of depression and diabetes complications: a meta-analysis
de Groot, M., Anderson, R., Freedland, K. E., Clouse, R. E., & Lustman, P. J. (2001) · Psychosomatic Medicine · doi:10.1097/00006842-200107000-00015 · Cited by 1,799
Stanghellini, V., Chan, F. K. L., Hasler, W. L., Malagelada, J. R., Suzuki, H., Tack, J., & Talley, N. J. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.011 · Cited by 1,572
Dyck, P. J., Kratz, K. M., Karnes, J. L., Litchy, W. J., Klein, R., Pach, J. M., Wilson, D. M., O'Brien, P. C., & Melton, L. J. (1993) · Neurology · doi:10.1212/wnl.43.4.817 · Cited by 1,482
Clinical Guideline: Management of Gastroparesis
Camilleri, M., Parkman, H. P., Shafi, M. A., Abell, T. L., & Gerson, L. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.373 · Cited by 1,149
Azithromycin and the Risk of Cardiovascular Death
Ray, W. A., Murray, K. T., Hall, K., Arbogast, P. G., & Stein, C. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1003833 · Cited by 954
Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Cited by
Advances in oral peptide therapeutics
Drucker, D. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0053-0 · Cited by 646
Diabetic neuropathy: cutting-edge research and future directions
Yang, Y., Zhao, B., Wang, Y., Lan, H., Liu, X., Hu, Y., & Cao, P. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02175-1 · Cited by 234
Prevention of Microvascular Complications of Diabetes
Crasto, W., Patel, V., Davies, M. J., & Khunti, K. (2021) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.05.005 · Cited by 166
The Impact of Microbiota on the Gut–Brain Axis: Examining the Complex Interplay and Implications
Chaudhry, T. S., Senapati, S. G., Gadam, S., Mannam, H. P. S. S., Voruganti, H. V., Abbasi, Z., Abhinav, T., Challa, A. B., Pallipamu, N., Bheemisetty, N., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165231 · Cited by 120
“Dietary changes, prokinetics, antiemetics, and neuromodulators are found to be most helpful in patients with gastroparesis [44,46] Nausea and vomiting are frequently associated with neurological disorders [47].”
BackgroundProgress in peptide and protein therapeutics: Challenges and strategies
Liu, M., Svirskis, D. M., Proft, T., Loh, J. M. S., Yin, N., Li, H., Li, D., Zhou, Y., Chen, S., Song, L., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.10.026 · Cited by 133
Metadata
- Authors
- Bharucha, A. E., Kudva, Y. C., & Prichard, D. O.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Bharucha, Adil E
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2019-05-13
- Volume
- 40
- Issue
- 5
- Pages
- 1318-1352
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC6736218
- OpenAlex
- W4211130106
- Cited by
- 252
- References
- 371
- Citations by year
- 2026: 43 · 2025: 47 · 2024: 39 · 2023: 42 · 2022: 26 · 2021: 33 · 2020: 13 · 2019: 8
- FWCI
- 3.66
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (PO1 DK68055)
- Topics
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic gastroparesis, delayed gastric emptying, dyspepsia, autonomic neuropathy, hyperglycemia, gastric motility, prokinetic agents, antiemetics, nutritional support, gastric electrical stimulation, ghrelin receptor agonist, serotonin receptor agonists, quality of life, anxiety and depression
- MeSH terms
- Animals, Diabetic Neuropathies, Female, Humans, Male, Gastroparesis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Diabetic Gastroparesis. https://app.cochat.ai/papers/10.1210/er.2018-00161
- The paper
- Bharucha, A. E., Kudva, Y. C., & Prichard, D. O. (2019). Diabetic Gastroparesis. Endocrine Reviews. https://doi.org/10.1210/er.2018-00161
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.